

September 1, 2023

## Santen Announces Status of Share Buyback

Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; President and CEO: Takeshi Ito) announced status of the share buyback as stated below. The share buyback was implemented in accordance with Article 156 of the Companies Act (Japan), as applied pursuant to Article 165, paragraph 3.

1. Class of shares repurchased	: Common shares	
2. Total number of shares repurchased: 1,859,800 shares		
3. Total amount of repurchase	: 2,439,772,200 yen	
4. Period of repurchase	: August 1, 2023 to August 31, 2023	
	(execution date basis)	
5. Method of repurchase	: Open-market repurchase by the discretionary	
	trading method	

## (Reference)

1. Details of the resolution at the meeting of the Board of Directors (announced on May 11, 2023)

Class of shares to be repurchased	: Common shares
Total number of shares to be repurchased	: 18,750,000 shares (maximum)
	*Representing 5.0% of the total number of
	shares outstanding (excluding treasury shares)
Total amount of repurchase	: 24.5 billion yen (maximum)
Period of repurchase	: May 12, 2023 to March 22, 2024
	Class of shares to be repurchased Total number of shares to be repurchased Total amount of repurchase Period of repurchase

2. Total Company's own shares repurchased through August 31, 2023, pursuant to the above Board resolution

(1) Total number of shares repurchased :	8,285,900 shares
------------------------------------------	------------------

(2) Total amount of repurchase: : 10,401,802,050 yen

**Contact:** Guillaume Sakuma Global Head of IR, IR Group E-mail: <u>ir@santen.com</u>

## About Santen

As a specialized company dedicated to eye health, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries and regions.

Toward realizing "WORLD VISION" (Happiness with Vision), the world Santen ultimately aspires to achieve, as a "Social Innovator", Santen aims to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world.

With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society.

For more information, please visit Santen's website (https://www.santen.com/en).